Patents by Inventor Philip Ronald Tempest

Philip Ronald Tempest has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof
    Patent number: 7605234
    Abstract: Specific binding members, featuring certain residues of the third CDR of the antibody NH576 (portions of SEQ ID NO:2) are provided, together with their use in methods of treatment and diagnosis.
    Type: Grant
    Filed: July 13, 2004
    Date of Patent: October 20, 2009
    Assignee: Peregrine Pharmaceuticals, Inc.
    Inventors: Andrew James Williams, Philip Ronald Tempest, Thor Las Holtet, Helen Jackson
  • Human antibodies specific for TGF?2
    Patent number: 7368111
    Abstract: Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGF?) bind specifically isoforms TGF?2 and TGF?1 or both, preferentially compared with TGF?3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGF?2, neutralizing its activity, but does not bind the latent member.
    Type: Grant
    Filed: July 23, 2003
    Date of Patent: May 6, 2008
    Assignees: Cambridge Antibody Technology Limited, Medical Research Council
    Inventors: Julia Elizabeth Thompson, Tristan John Vaughan, Andrew James Williams, Jonathan Alexander Green, Ronald Henry Jackson, Louise Bacon, Kevin Stuart Johnson, Alison Jane Wilton, Philip Ronald Tempest, Raymond Paul Field, Steven Paul Ruddock, Gregory Paul Winter
  • Specific binding members for TGF?
    Patent number: 7151169
    Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF?1 and are useful in treating conditions associated with excess TGF?1 activity, such as fibrosis, immune responses and tumor progression.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: December 19, 2006
    Assignee: Cambridge Antibody Technology Limited
    Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
  • Specific binding proteins including antibodies which bind to the necrotic center of tumors, and uses thereof
    Patent number: 6827925
    Abstract: Specific binding members, based on the third CDR of the antibody NHS76 (SEQ ID NO: 2) are provided, together with their use in methods of treatment and diagnosis.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: December 7, 2004
    Assignee: Cambridge Antibody Technology Limited
    Inventors: Andrew James Williams, Philip Ronald Tempest, Thor Las Holtet, Helen Jackson
  • Specific binding members for TGFbeta1
    Publication number: 20030091566
    Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10).
    Type: Application
    Filed: September 13, 2002
    Publication date: May 15, 2003
    Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
  • Specific binding members for TGFbeta1
    Publication number: 20030064069
    Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10).
    Type: Application
    Filed: September 13, 2002
    Publication date: April 3, 2003
    Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
  • Specific binding members for TGFbeta1
    Patent number: 6492497
    Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralizing activity for TGF&bgr;1 and are useful in treating conditions associated with excess TGF&bgr;1 activity, such as fibrosis, immune responses and tumor progression.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: December 10, 2002
    Assignee: Cambridge Antibody Technology Limited
    Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest